Preclinical Quality, Safety, and Efficacy of a Human Embryonic Stem Cell-Derived Product for the Treatment of Parkinson’s Disease, STEM-PD

Scientists presented quality, safety, and efficacy data supporting the first-in-human STEM-Parkinson’s disease phase I/IIa clinical trial along with the trial design.